UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

The Lancet (British edition), 2015-10, Vol.386 (10005), p.1754-1764

2015

Volltextzugriff (PDF)

Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders

Pharmacotherapy, 2016-09, Vol.36 (9), p.1028-1041

2016

Volltextzugriff (PDF)

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist

Journal of clinical pharmacology, 2015-09, Vol.55 (9), p.1004-1011

2015

Volltextzugriff (PDF)

Absolute Bioavailability of Tasimelteon

American journal of therapeutics, 2015-09, Vol.22 (5), p.355-360

2015

Volltextzugriff (PDF)

Safety profile of tasimelteon, a melatonin MT 1 and MT 2 receptor agonist: pooled safety analyses from six clinical studies

Expert opinion on drug safety, 2015-11, Vol.14 (11), p.1673-1685

2015

Volltextzugriff (PDF)

Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies

Expert opinion on drug safety, 2015-11, Vol.14 (11), p.1673-1685

2015

Volltextzugriff (PDF)

Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer

Cancer research (Chicago, Ill.), 2003-05, Vol.63 (9), p.2194-2199

2003

Volltextzugriff (PDF)

Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib

Clinical cancer research, 2004-01, Vol.10 (1), p.155-165

2004

Volltextzugriff (PDF)

Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)

Clinical cancer research, 2004-04, Vol.10 (7), p.2265-2271

2004

Volltextzugriff (PDF)

Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT039-CT039

2023

Volltextzugriff (PDF)

Le tasimelteon entraîne l’horloge circadienne et procure une amélioration significative aux personnes totalement aveugles, souffrant du libre-cours

Médecine du sommeil, 2015-01, Vol.12 (1), p.55-56

2015

Volltextzugriff (PDF)

Étude de sécurité, multicentrique, en ouvert, du tasimelteon pour le traitement du syndrome libre-cours chez les personnes totalement aveugles

Médecine du sommeil, 2015-01, Vol.12 (1), p.55

2015

Volltextzugriff (PDF)

Translating the genome into individualized therapeutics: R&D Activities Within Singapore's BioMedical Science Initiative

Drug development research, 2004, Vol.62 (4), p.371-382

2004

Volltextzugriff (PDF)

Translating the Genome into individualized therapeutics

Drug development research, 2004-08, Vol.62 (4), p.371-382

2004

Volltextzugriff (PDF)

Signing on to expression profiles

Nature genetics, 1999-11, Vol.23 (S3), p.42-42

1999

Volltextzugriff (PDF)

Ocrl1, a PtdIns(4,5)P 2 5-Phosphatase, Is Localized to the Trans -Golgi Network of Fibroblasts and Epithelial Cells

The journal of histochemistry and cytochemistry, 2000-02, Vol.48 (2), p.179-189

2000

Volltextzugriff (PDF)

Ocrl1, a PtdIns(4,5)P2 5-Phosphatase, Is Localized to the Trans-Golgi Network of Fibroblasts and Epithelial Cells

The journal of histochemistry and cytochemistry, 2000-02, Vol.48 (2), p.179-189

2000

Volltextzugriff (PDF)

Patient Demographics and Clinical Characteristics of Adults With Spinal Muscular Atrophy (SMA): An Assessment of Patients Receiving Risdiplam Treatment and Untreated Patients With SMA (P2-11.004)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Vascular Remodeling in Response to 12 wk of Upper Arm Unilateral Resistance Training

Medicine and science in sports and exercise, 2009-11, Vol.41 (11), p.2003-2008

2009

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(20)

Sprache

Englisch
(18)
Französisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist

Absolute Bioavailability of Tasimelteon

Safety profile of tasimelteon, a melatonin MT 1 and MT 2 receptor agonist: pooled safety analyses from six clinical studies

Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies

Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer

Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib

Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)

Le tasimelteon entraîne l’horloge circadienne et procure une amélioration significative aux personnes totalement aveugles, souffrant du libre-cours

Étude de sécurité, multicentrique, en ouvert, du tasimelteon pour le traitement du syndrome libre-cours chez les personnes totalement aveugles

Translating the genome into individualized therapeutics: R&D Activities Within Singapore's BioMedical Science Initiative

Translating the Genome into individualized therapeutics

Signing on to expression profiles

Ocrl1, a PtdIns(4,5)P 2 5-Phosphatase, Is Localized to the Trans -Golgi Network of Fibroblasts and Epithelial Cells

Ocrl1, a PtdIns(4,5)P2 5-Phosphatase, Is Localized to the Trans-Golgi Network of Fibroblasts and Epithelial Cells

Patient Demographics and Clinical Characteristics of Adults With Spinal Muscular Atrophy (SMA): An Assessment of Patients Receiving Risdiplam Treatment and Untreated Patients With SMA (P2-11.004)

Vascular Remodeling in Response to 12 wk of Upper Arm Unilateral Resistance Training

Suchergebnisse filtern